U.S. Labor Secretary Visits Niowave to Discuss Advanced Manufacturing and Biotech Innovations

Highlighting the Future of Manufacturing at Niowave

On October 15, 2026, Niowave, a leader in the production of medical radioisotopes, hosted U.S. Labor Secretary Keith Sonderling at their state-of-the-art facility in Lansing, Michigan. The visit was aimed at showcasing how the company is at the forefront of advanced manufacturing and biotechnology, specifically in creating innovative solutions for cancer treatment.

During the tour, Secretary Sonderling observed the current production capabilities and the ongoing construction of a new facility dedicated to medical radioisotope production. Niowave's commitment to enhancing the domestic supply of critical isotopes was a central theme of the discussions. The new facility, with a staggering investment of over $85 million, is expected to significantly boost production capacity and employ at least 73 individuals, with starting wages set notably above the regional median.

Innovations in Cancer Treatment

As part of the roundtable discussions, the executives from Niowave shared insights into their operations and the vital role of Actinium-225, a critical isotope utilized in targeted alpha therapies for cancer. This isotope's production capabilities are projected to accelerate significantly with the addition of six new linear particle accelerators in the facility. The overarching aim is not just to maintain but to lead in the fight against cancer through reliable and scalable supply chains.

Mike Zamiara, President and CEO of Niowave, expressed pride in showcasing the expertise and manufacturing tradition present in Mid-Michigan. He emphasized that the company's innovations are pivotal for addressing some of the most challenging health issues today. The focus remains on combining skilled labor with advanced technologies to manufacture the next generation of cancer treatments effectively.

Community Impact and Workforce Development

The construction project is bolstered by a $695,000 performance-based grant from the Michigan Business Development Program, complemented by additional funding aimed at enhancing local infrastructure. This comprehensive approach to development not only supports the company's growth but also aims to cultivate Michigan's highly skilled workforce, particularly in technical roles critical to advanced manufacturing and biotechnology.

The planned facility will encompass approximately 80,000 square feet, including extensive production spaces, radiochemistry laboratories, and administrative offices to support operations. These developments signify a progressive step towards maintaining Michigan's reputation as a hub for innovation in both manufacturing and healthcare.

Looking Ahead

Scheduled to become operational by 2028, the new facility represents a major leap forward in Niowave's mission to enhance cancer treatment options. The company's long-term objectives include expanding their influence in the medical isotope market, fostering new partnerships, and ultimately contributing to improved health outcomes for patients battling cancer.

As Secretary Sonderling left the facility, it was clear that his visit served not only to highlight the advancements at Niowave but also to affirm the critical connection between skilled workforce development and groundbreaking healthcare progress. Niowave continues to stand at the intersection of manufacturing, biotechnology, and healthcare solutions, providing a beacon of hope in the fight against cancer.

By investing in its workforce and pushing the boundaries of technology, Niowave is poised to make a lasting impact on the future of treatment for cancer patients worldwide.